TABLE 7.
Relationship between synergistic effect and blaC and dacB2 mutation
| Locus | Sequence change | Amino acid change | No. of isolates (%)a | Ratio rangeb |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMX-CLAV | AMX-SUB | AMX-TAZ | IMI-CLAV | IMI-SUB | IMI-TAZ | MERO-CLAV | MERO-SUB | MERO-TAZ | BIA-CLAV | BIA-SUB | BIA-TAZ | ||||
| BlaC | AGT333AGG | Ser111Arg | 4 (3.3) | 0.13–0.25 | 0.13 | 0.25 | 1 | 1 | 0.5–1 | 0.031 | 0.5 | 0.5 | 0.25 | 0.12–0.25 | 0.13–0.25 |
| ATC786ATT | Ile262Ile | 9 (7.4) | 0.5–1 | 0.13 | 0.25–0.5 | 1 | 0.5–1 | 0.5–1 | 0.25–1 | 0.5 | 0.5 | 0.25–0.5 | 0.13–0.5 | 0.13–0.5 | |
| DacB2 | CTG659CAG | Leu220Gln | 8 (6.6) | 0.13–1 | 0.13 | 0.25–0.5 | 1 | 0.5–1 | 0.5–1 | 0.25–1 | 0.5 | 0.5 | 0.25–0.5 | 0.13–0.5 | 0.13–0.5 |
a
A total of 121 isolates were used.
b
Ratio represents the MIC value with β-lactamase inhibitor divided by the MIC value without β-lactamase inhibitor.